Bryce Harrison Email & Phone Number

Boston, MA, US

Waltham, Massachusetts, United States

Waltham, Massachusetts, United States

Waltham, Massachusetts, United States

Greater Boston Area

Waltham, MA

• Chemistry project lead for hit-to-lead efforts on novel target for frontotemporal dementia
• Coordinated project efforts with biology and DMPK
• Triaged screening hits and designed hybrid analogs using structure-based docking in MOE software
• Directed synthesis of targets at 2 CROs

Waltham, MA

• Co-inventor of gamma secretase modulator preclinical candidate for Alzheimer’s disease and co-inventor of alpha 7 nicotinic receptor agonist preclinical candidate for cognitive enhancement.
• Designed key analogs that advanced the SAR towards the candidates
• Directed two 4 FTE teams at European CRO, and co-led 16 FTE team at Asian CRO. Developed novel synthetic routes for lead series and prepared novel analogs
• Managed scale-up of both candidates on 400 g scale at Asian CRO
• Compiled and edited experimental sections for 6 patent applications. Co-inventor on all 6 applications.Participated in planning process for potential internal chemistry labs
• Identified and evaluated equipment and instruments for internal lab setup

Princeton, NJ

• Part of the discovery team of LX2761, locally acting SGLT1 inhibitor, clinical candidate for diabetes
• Played support role to chemistry lead.
• Made key laboratory contributions to the discovery of the clinical candidate
• Co-inventor on composition of matter patentProject manager for collaboration with 6 FTE team at SAI Life Sciences in India
• Coordinated between internal group leaders and SAI chemists for the scale-up of key intermediates and reference compounds.
• Reviewed reports and analytical data, conducted telecoms, and assisted in trouble-shooting of difficult reactions.Chemistry lead for a dry AMD ophthalmology project targeting an ion channel

Princeton, NJ

• Chemistry lead for the discovery team of LX7101, LIM-kinase inhibitor, completed phase 1 clinical trials for glaucoma
• Directed chemistry efforts toward the identification of the clinical candidate
• Coordinated discovery efforts with leads from ophthalmology, pharmaceutical discovery, and DMPK
• Presented chemistry updates in working group meetings and to senior management
• Prepared chemistry section of composition of matter patent, co-inventor on patent
• Supervised 2 associate level direct reports

Princeton, NJ

• Key contributor to the discovery of Sotagliflozin (LX4211), first-in-class dual SGLT1/2 inhibitor, phase 3 for diabetes.
• Developed stereoselective route to D-xylosides that enabled the discovery of the clinical candidate
• Supervised associate level direct report who first prepared both the first compound in the primary series and the clinical candidate
• Helped develop improved 12 step stereoselective synthesis of the compound, including novel chemistry for the stereoselective formation of beta thioglycosides
• Co-inventor on both the composition of matter patent and the process patent
• Identified backup series of aza sugars

Princeton, NJ

Advisor: Professor Erik J. SorensenTotal synthesis of Abyssomicin C

Phd, Organic Chemistry

Advisor: Professor Gregory L. Verdine Thesis: The Synthesis and Biological Evaluation of Exhaustively Stereodiversified Libraries of.

Bs, Chemistry

Advisor: Professor Paul B. Savage Undergraduate research: Synthesis of Lipid A Analogs